Molecule that dilates blood vessels hints at new way to treat heart disease

Molecule that dilates blood vessels hints at new way to treat heart disease LA JOLLA, CA April 19, 2018 Americans die of heart or cardiovascular disease at an alarming rate. In fact, heart attacks, strokes and related diseases will kill an estimated 610,000 Americans this year alone. Some medications help, but to better tackle this problem, researchers need to know exactly how the heart and blood vessels stay healthy in the first place.

Now, scientists at The Scripps Research Institute have identified a protein, called GPR68, that senses blood flow and tells small blood vessels called arterioles when to dilate. The researchers believe medications that activate GPR68 could one day be useful to treat medical conditions, including ischemic stroke.

It has been known for decades that blood vessels sense changes in blood flow rate, and this information is crucial in regulating blood vessel dilation and controlling vascular tone, says Ardem Patapoutian, PhD, Scripps Research professor, Howard Hughes Medical Institute investigator and senior author of the study published today in the journal Cell.

Indeed, flow-mediated dilation (FMD) is a non-invasive clinical test that informs doctors about the health of the vascular system. A compromised FMD is a precursor to a wide array of vascular diseases such as hypertension and atherosclerosis.

Despite the importance of this process, the molecules involved within arteries to sense blood flow have remained unknown, Patapoutian says.

Patapoutian and first author Jie Xu, PhD, a postdoctoral fellow in the lab, and now an independent scientist at the Genomics Institute of the Novartis Research Foundation (GNF), led the project to find GPR68 and determine how it works. The team started by designing a machine that uses turbulent movement of liquid to stand in for blood flow in blood vessels. This machine uses 384 pistons that move the fluid up and down over a bed of cells, placed in 384 wells on a plate. This motion simulates how blood would put pressure on those cells.

The researchers put this machine to work testing a series of cell lines, some of which had mutations that led to an overexpression of proteins potentially linked to pressure sensing. The researchers then performed a screen, knocking down the expression of different candidate genes in each of the 384 wells, and tested if that gene is required for responding to the machine's turbulent pressure.

The tests pointed the researchers to GPR68, which the authors showed works as a sensor of mechanical stimulation. Further experiments suggested that GPR68 is essential for FMD. In a model organism, this protein is essential for sensing blood flow, and the proper functioning of the vascular system, says Patapoutian.

When arterioles can't dilate properly, the body has fewer options for lowering blood pressure in people with hypertension or getting blood through clogged vessels in cases of atherosclerosis.

Future work will explore the role of GPR68 in clinically relevant cardiovascular diseases, Patapoutian says. We are also exploring the possibility of using small molecules to modulate the function of GPR68, as such molecules could be beneficial in the clinic.

The study, GPR68 Senses Flow and is Essential for Vascular Physiology, also included authors from GNF, the MITOVASC Institute; the Indiana University School of Medicine; and the University of California, San Diego.

The research was supported in part by the National Institutes of Health (grant R01 DE022358).

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the worlds largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine work toward their next discoveries. The institutes graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see www.scripps.edu.

# # #

For information:

Office of Communications

Tel: 858-784-2666

Fax: 858-784-8118

press@scripps.edu

LINK:	http://www.scripps.edu/news/press/2018/20180419_heart_disease.html...
	See more stories from scripps

Most recent headlines